Abeona Therapeutics receives FDA orphan designation for gene therapy – European Pharmaceutical Review
European Pharmaceutical Review |
Abeona Therapeutics receives FDA orphan designation for gene therapy
European Pharmaceutical Review The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Abeona Therapeutics's EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic epidermolysis … |
